title: Tetanus immunity among intravenous drug users in Guipuzcoa (Basque Country, Spain)
authors.forename: G
authors.initials: G
authors.lastname: Cilla
authors.forename: E
authors.initials: E
authors.lastname: Pérez-Trallero
authors.forename: J R
authors.initials: JR
authors.lastname: Sáenz-Dominguez
authors.forename: H
authors.initials: H
authors.lastname: Esparza
authors.forename: F
authors.initials: F
authors.lastname: Otero
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D001681:Biological Assay; D003017:Clostridium tetani / Q000276:immunology*; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D008297:Male; D051379:Mice; D008875:Middle Aged; D009313:National Health Programs; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000150:complications*; D013742:Tetanus / Q000453:epidemiology / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control; D013745:Tetanus Toxoid / Q000276:immunology; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D013745:Tetanus Toxoid